Quantitative Structure-Metabolism Relationship Analyses of MAO-Mediated Toxication of 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine and Analogues

Chemical Research in Toxicology

Volumn 5, Issue 3, 1992, Pages 366-375

  Altomare, Cosimo ^a,b   Carrupt, Pierre Alain ^a,b   Gaillard, Patrick ^a,b   El Tayar, Nabil ^a,b   Testa, Bernard ^a,b   Carotti, Angelo ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; PYRIDINE DERIVATIVE;

ARTICLE; IONIZATION; LIPOPHILICITY; PARTITION COEFFICIENT; STRUCTURE ACTIVITY RELATION; XENOBIOTIC METABOLISM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; CHEMISTRY, PHYSICAL; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MONOAMINE OXIDASE; MPTP POISONING; REGRESSION ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0026709245     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx00027a008     Document Type: Article

References (40)

1. Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., and Kopin, I. J. (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1, 249-254.
2. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. (1983) Chronic product of meperidine-analog synthesis. Science 219, 979-980.
3. Ballard, P. A., Langston, J. W., Tetrud, J., and Burns, R. S. (1983) Chemically induced chronic parkinsonism in young adults: clinical and neuropharmacologic aspects. Neurology 33 (Suppl. 2), 90.
4. Langston, J. W., and Ballard, P. (1984) Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11, 160-165.
5. Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., and Kopin, I. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 80, 4546-4550.
6. Kolata, G. (1983) Monkey model of Parkinson's disease. Science 220, 705.
7. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Science 224, 1451-1453.
8. Hallman, H., Lange, J., Olson, L., Stromberg, I., and Jonsson, G. (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J. Neurochem. 44, 117-127.
9. Maret, G., Testa, B., Jenner, P., El Tayar, N., and Carrupt, P. A. (1990) The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing Parkinsonism. Drug Metab. Rev. 22, 291-332.
10. Heikkila, R. E., Manzino, L., Cabbat, F., and Duvoisin, R. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
11. Maret, G., El Tayar, N., Carrupt, P. A., Testa, B., Jenner, P., and Baird, M. (1990) Toxication of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and analogs by monoamine oxidase. A structure-activity relationship study. Biochem. Pharmacol. 40, 783-792.
12. Marshall, G. R., and Cramer, R. D., III (1988) Three-dimensional structure-activity relationships. Trends Pharmacol. Sci. 9, 285-289.
13. Cramer, R. D., III, Patterson, D. E., and Bunce, J. D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110, 5959-5967.
14. Heikkila, R. E., Kindt, M. V., Sonsalla, P. K., Giovanni, A., Youngster, S. K., McKeown, K. A., and Singer, T. P. (1988) Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 85, 6172-6176.
15. Efange, S. M. N., and Boudreau, R. J. (1991) Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Comput.-Aided Mol. Des. 5, 405-417.
16. Singer, T. P., and Ramsay, R. R. (1991) The interaction of Monoamine Oxidases with tertiary amines. Biochem. Soc. Trans. 19, 211-214.
17. Vallat, P., El Tayar, N., Testa, B., Slacanin, I., Marston, A., and Hostettmann, K. (1990) Centrifugal counter-current chromatography, a promising means of measuring partition coefficients. J. Chromatogr. 504, 411-419.
18. Hansch, C., and Leo, A. (1979) The FRAGMENT method of calculating Partition Coefficients. In Substituent constants for correlation analysis in chemistry and biology, pp 18-43, Wiley-Interscience, New York.
19. Walther, B., Carrupt, P. A., El Tayar, N., and Testa, B. (1989) 8-Substituted xanthines as phosphodiesterase inhibitors: Conformation-dependent lipophilicity and structure-activity relationships. Helv. Chim. Acta 72, 507-517.
20. Benet, L. Z., and Goyan, J. E. (1967) Potentiometric determination of dissociation constants. J. Pharm. Sci. 56, 665-680.
21. Leeson, L. J., and Brown, M. (1966) Some observations on nonlogarithmic titration curves for the determination of dissociation constants and purity. J. Pharm. Sci. 55, 431-433.
22. Motoc, I., Demmkoelher, R. A., Mayer, D., and Labanowski, J. (1986) Three-dimensional quantitative structure-activity relationships. 1. General approach to the pharmacophore model validation. Quant. Struct.-Act. Relat. 5, 99-105.
23. Labanowski, J., Motoc, I., Naylor, C. B., Mayer, D., and Dammkoelher, R. A. (1986) Three-dimensional quantitative structure-activity relationships. 2. Conformational mimicry and topographical similarity of flexible molecules. Quant. Struct.-Act. Relat. 5, 138-152.
24. Dunn, W. J., III, Wold, S., Edlund, U., and Hellberg, S. (1984) Multivariate structure-activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: the PLS method. Quant. Struct.-Act. Relat. 3, 131-137.
25. Cramer, R. D., III, Bunce, J. D., and Patterson, D. E. (1988) Crossvalidation, bootstrapping, and Partial Least Squares compared with multiple regression in conventional QSAR Studies. Quant. Struct.-Act. Relat. 7, 18-25.
26. Mager, H., and Barth, A. (1979) Problems Involved in the Specification and Interpretation of Quantitative Structure-activity Relationships. Pharmazie 34, 557-559.
27. Altomare, C., Tsai, R. S., El Tayar, N., Testa, B., Carotti, A., Cellamare, S., and De Benedetti, P. G. (1991) Lipophilicity and hydrogen-bond donor acidity of bioactive sulfonyl-containing compounds. Experimental determination by RP-HPLC and CCCC and application to structure-activity relationships. J. Pharm. Pharmacol. 43, 191-197.
28. El Tayar, N., Tsai, R. S., Vallat, P., Altomare, C., and Testa, B. (1991) Measurements of partition coefficients by various Centrifugal Partition Chromatographic techniques: a comparative evaluation. J. Chromatogr. 556, 181-194.
29. Riachi, J. N., LaManna, J. C., and Harik, S. I. (1989) Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. J. Pharmacol. Exp. Ther. 249, 774-748.
30. Fersht, A. (1985) The basic equations of enzyme kinetics. In Enzyme structure and mechanism, pp 105-106, W. H. Freeman and Co., New York.
31. Selassie, C. D., Li, R.-L., Poe, M., and Hansch, C. (1991) On the optimization of hydrophobic and hydrophilic interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase. J. Med. Chem. 34, 46-54.
32. van de Waterbeemd, H., and Testa, B. (1987) The parametrization of lipophilicity and other structural properties in drug design. In Advances in Drug Research (Testa, B., Ed.) Vol. 17, pp 85-225, Academic Press, London.
33. Dearden, J. C., Bradhurne, S. J. A., and Abraham, M. H. (1991) The nature of molar refractivity. Pharmacochem. Libr. 16 (QSAR: Ration. Approaches Des. Bioact. Compd., Proc. Eur. Symp. Quant. Struct.-Act. Relat. 8th, 1990), 143-150.
34. Hansch, C., and Klein, T. (1986) Molecular Graphics and QSAR in the study of enzyme-ligand interactions. On the definition of bioreceptors. Acc. Chem. Res. 19, 392-400.
35. Lindberg, W., Persson, J.-A., and Wold, S. (1983) Partial least-squares method for spectrofluorimetric analysis of mixtures of humic acid and ligninsulfonate. Anal. Chem. 55, 643-648.
36. Cramer, R. D., III, Clark, M., Simeroth, P., and Patterson, D. E. (1991) Recent developments in Comparative Molecular Field Analysis. Pharmacochem. Libr. 16, (QSAR: Ration. Approaches Des. Bioact. Compd., Proc. Eur. Soc. Quant. Struct.-Act. Relat. 8th, 1990), 239-242.
37. Rowberg, K. L., and Hopfinger, A. J. (1990) An investigation into the generalizability of quantitative structure-activity relationships developed for dihydropteridine reductase inhibitors. Chemom. Intell. Lab. Syst. 8, 183-194.
38. Klein, C., Borne, R., and Steven, R. E. (1985) Structure of a neurotoxin that induces parkinsonism symptoms: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride. Pharm. Res. 2, 192-194.
39. Fowler, C. J., and Tipton, K. F. (1984) On the substrate specificities of the two forms of monoamines oxidase. J. Pharm. Pharmacol. 36, 111-115.
40. Bach, A. W., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S. W., Seeburg, P. H., and Shih, J. C. (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of difference in enzymatic peoperties. Proc. Natl. Acad. Sci. U.S.A. 85, 4934-4938.